Experimental agents under development for patients with relapsed/refractory CLL
| Name . | Mechanism . | ORR in patients with R/R CLL . | Currently evaluated in BKTi/BCL2i refractory patients with CLL . | Clinical trial registration number . |
|---|---|---|---|---|
| Lisaftoclax | BCL2 inhibitor | Not available | No | NCT05147467 |
| BGB-11417 | BCL2 inhibitor | 2/6 (monotherapy) 12/19 (in combination with zanubrutinib) | Yes | NCT04277637 |
| LOXO-338 | BCL2 inhibitor | Not available | No | NCT05024045 |
| Epcoritamab | CD20 × CD3 bispecific monoclonal antibody | Not available | Yes | NCT04623541 |
| Mosunetuzumab | CD20 × CD3 bispecific monoclonal antibody | Not available | Yes | NCT05091424 |
| BGB-16673 | BTK degrader | Not available | Yes | NCT05006716 |
| NX-2127 | BTK degrader and IMiD | Not available | Yes | NCT04830137 |
| NX-5948 | BTK degrader | Not available | Yes | NCT05131022 |
| Zilovertamab | Anti-ROR1 monoclonal antibody | 31/34 (including both 12 TN and 22 R/R patients) | No | NCT03088878 |
| VIP152 | CDK9 inhibitor | Not available | Yes | NCT04978779 |
| Name . | Mechanism . | ORR in patients with R/R CLL . | Currently evaluated in BKTi/BCL2i refractory patients with CLL . | Clinical trial registration number . |
|---|---|---|---|---|
| Lisaftoclax | BCL2 inhibitor | Not available | No | NCT05147467 |
| BGB-11417 | BCL2 inhibitor | 2/6 (monotherapy) 12/19 (in combination with zanubrutinib) | Yes | NCT04277637 |
| LOXO-338 | BCL2 inhibitor | Not available | No | NCT05024045 |
| Epcoritamab | CD20 × CD3 bispecific monoclonal antibody | Not available | Yes | NCT04623541 |
| Mosunetuzumab | CD20 × CD3 bispecific monoclonal antibody | Not available | Yes | NCT05091424 |
| BGB-16673 | BTK degrader | Not available | Yes | NCT05006716 |
| NX-2127 | BTK degrader and IMiD | Not available | Yes | NCT04830137 |
| NX-5948 | BTK degrader | Not available | Yes | NCT05131022 |
| Zilovertamab | Anti-ROR1 monoclonal antibody | 31/34 (including both 12 TN and 22 R/R patients) | No | NCT03088878 |
| VIP152 | CDK9 inhibitor | Not available | Yes | NCT04978779 |
CDK9, cyclin-dependent kinase 9; IMiD, immunomodulatory drug; TN, treatment-naive.